Business

A summer rally may be underway. Economic forecaster Lakshman Achuthan cites a bullish, under-the-radar trend in a chart highlighting the firm’s special weekly leading index and S&P 500. “This is a fundamentally optimistic chart,” the Economic Cycle Research Institute co-founder told CNBC’s “Trading Nation” on Monday. “It’s showing us that the cyclical fundamentals are to
0 Comments
The average age of new coronavirus patients has dropped by roughly 15 years compared with only a few months ago as the coronavirus reignites in America’s Sun Belt, White House health advisor Dr. Anthony Fauci said Monday. Fauci, director of the National Institutes of Allergy and Infectious Diseases, said during a Q&A discussion with Dr. Francis
0 Comments
Justin Paget | Getty Images Children diagnosed with Covid-19 pediatric multisystem inflammatory syndrome, or PMIS, may develop new neurological problems without any of the respiratory issues commonly associated with the virus, according to a study published Wednesday in the Journal of the American Medical Association.  Researchers examined 27 children with Covid-19 PMIS, who were previously healthy, between
0 Comments
The worst of the U.S. coronavirus outbreak will end by January either with a vaccine or because enough people in the country will have already been infected and have some immunity to it, former Food and Drug Administration Commissioner Dr. Scott Gottlieb told CNBC on Thursday. The restrictions and guidance implemented to curb the spread
0 Comments
U.S. and China flags along Pennsylvania Avenue in Washington, D.C. on Jan. 17, 2011. Andrew Harrer | Bloomberg | Getty Images Delisting Chinese companies from U.S. stock exchanges is “a pointless drive” that will neither deny those firms access to American capital markets nor hurt China’s growth, according to a report by think tank Peterson Institute for
0 Comments
Moderna‘s stock fell by as much as 9.4% in midday trading Thursday after a report said the biotech company’s late-stage trial for a potential coronavirus vaccine will be delayed, possibly by a few weeks. The company, which is working with the National Institutes of Health, was expected to begin a phase 3 trial with 30,000 participants for
0 Comments